Skip to main content
Premium Trial:

Request an Annual Quote

Rolf Apweiler, Mathew Hahn, Scott Kahn, Jeff Augen, David Evans, and more


The Human Proteome Organization has elected Rolf Apweiler of the European Bioinformatics Institute as its next president. Apweiler is currently chair of HUPO's Proteomics Standards Initiative and leads the sequence database group at EBI, where he heads the UniProt/SwissProt database. He will take the helm at HUPO on Jan. 1, 2007, for two years, replacing John Bergeron.

Accelrys has promoted Mathew Hahn to the position of chief science and technology officer. Scott Kahn, the company's former CSO, joined Illumina as vice president and chief information officer in April. Hahn co-founded SciTegic, which Accelrys acquired in September. Hahn joined Accelrys at the time as general manager of the SciTegic subsidiary, but his association with the firm extends back to 1989, when he joined Molecular Simulations, where he led product development efforts for 10 years. Hahn will remain general manager of the SciTegic subsidiary, and continue to lead the development and marketing of its Pipeline Pilot product, Accelrys said.

Jeff Augen has stepped down as president of TurboWorx for medical reasons, the company said in August. Augen was previously worldwide director of strategy for IBM's life sciences business unit. The company has tapped Srini Chari as its new president and CEO. Chari joined the company in 2003 as vice president of technical operations. Chari previously served as program director for emerging businesses and corporate strategy at IBM, and senior manager of architecture and strategy for IBM's life sciences business unit at IBM.

The company announced a number of additional management changes. Andrew Sherman, a company founder, was promoted to vice president of development and chief technical officer. Previously, he was responsible for technical product R&D and internal operations.

Jason Alter has been promoted from marketing director to vice president of marketing and professional services. He also joined TurboWorx in March from IBM, where he was most recently manager of program marketing for the healthcare and life sciences business unit.

Gourish Hosangady, formerly vice president of channels and alliances, has been appointed vice president of sales. He joined TurboWorx in 2004 and previously served as CEO and managing director of SAS India.

The company also hired Mary Anne Sulik as chief financial officer and vice president of business operations.

Physiomics has appointed David Evans as non-executive chairman. He succeeds Stephen Parker, who recently became a partner of Celtic Pharma Management, a private equity fund specializing in late-stage pharmaceutical projects. Evans was previously managing director of Shield Diagnostics, and then managing director of the company following its merger with Axis in 1999 to create Axis-Shield.

Laureate Pharma has appointed Michael Cavanaugh as vice president of sales, marketing, and business development. Cavanaugh most recently served as vice president of marketing and sales support for North America with Amersham/GE Healthcare, where he was responsible for instruments and reagents for genomics, proteomics, screening, cellular analysis, and preclinical imaging. Prior to that, Cavanaugh was senior director of business development, Europe, at Gene Logic.

John DiBella has moved from the position of life sciences product manager to marketing and sales field representative at Simulations Plus. DiBella was product manager and primary scientist for the development of the company's DDDPlus software product. "Although I've enjoyed the software development side of the business, I believe I can offer even more to the company as a field representative," DiBella said in a statement.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.